sensei(US:SNSE) Globenewswire·2025-10-30 13:00Core Viewpoint - Sensei Biotherapeutics has decided to discontinue the development of solnerstotug and is initiating a strategic review to maximize shareholder value, which may include various options such as asset sales or mergers [1][3]. Company Overview - Sensei Biotherapeutics is a clinical-stage biotechnology company focused on developing next-generation therapeutics for cancer patients [4]. Strategic Review and Workforce Reduction - The company plans to implement a workforce reduction to preserve cash, retaining a small team to assist in exploring strategic alternatives and managing the cessation of development activities [2]. - The strategic review may lead to various outcomes, including a sale of assets, licensing arrangements, or a merger, but there is no definitive timeline for this process [1][3]. Clinical Development Status - Solnerstotug has shown clinical activity in a patient population with significant unmet needs, but the company has decided not to initiate new clinical studies due to funding needs and the current capital markets environment [3].